Topic: Eli Lilly

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in pharmaceutical production.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

Zepbound, a drug used to help patients lose weight and manage diabetes, may also help those with heart failure, a new trial shows.

British Prime Minister Keir Starmer kicked off an international business investment summit aimed at pulling in billions of dollars of foreign money to kickstart Britain's stagnant economy by pledging to slash bureaucracy

Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development facility in Lebanon, Indiana expected to open in late 2027.

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP-1 medicines like Ozempic can help stop that.

Weekly insulin shots can help control both Type 1 and Type 2 diabetes as well as daily injections do, a pair of clinical trials have found.

Eli Lilly, maker of one of the blockbuster GLP-1 weight-loss drug Zepbound, says it will now offer the medication in single-dose vials at half the price currently available to consumers.